Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib versus placebo with first-line chemotherapy and/or endocrine therapy for recurrent or metastatic breast cancer
2007-001416-23Phase 2Terminated
- Sponsor
- Michelangelo Foundation
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Sorafenib + standard first-line therapy with Placebo + standard first-line therapy (2 arms). Primary endpoint: Progression-free survival. Started Aug 2007; status: terminated.
02
Drugs
sorafenib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-001416-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001416-23.